Cost Effectiveness of Rituximab Therapy for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Cost-Utility Studies

ConclusionRituximab is cost effective compared to other DMARDs but not if used as third-line therapy after failure of biologics. There is a need to generate context-specific evidence for the lower income settings.

http://link.springer.com/10.1007/s40261-022-01238-3

Source: Clinical Drug Investigation - January 9, 2023 Category: Drugs & Pharmacology Source Type: research